CoChat

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma

Open access
Bria, Emilio, Pilotto, Sara, Amato, Eliana, Fassan, Matteo, Novello, Silvia, Peretti, Umberto, Vavalà, Tiziana, Kinspergher, Stefania, Righi, Luisella, Santo, Antonio, Brunelli, Matteo, Corbo, Vincenzo, Giglioli, Eliana, Sperduti, Isabella, Milella, Michele, Chilosi, Marco, Scarpa, Aldo, Tortora, Giampaolo · 2015 · Oncotarget
Cited by 73

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

// Emilio Bria 1,* , Sara Pilotto 1,* , Eliana Amato 2 , Matteo Fassan 2 , Silvia Novello 3 , Umberto Peretti 1 , Tiziana Vavalà 3 , Stefania Kinspergher 1 , Luisella Righi 3 , Antonio Santo 1 , Matteo Brunelli 4 , Vincenzo Corbo 2 , Eliana Giglioli 4 , Isabella Sperduti 5 , Michele Milella 6 , Marco Chilosi 4 , Aldo Scarpa 2,4 and Giampaolo Tortora 1 1 Department of Medicine, Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy 2 ARC-NET Center for Applied Research on Cancer, University and Azienda Ospedaliera Universitaria Integrata, Verona, Italy 3 Department of Oncology, University of Torino, A.O.U. San Luigi, Orbassano, Torino, Italy 4 Department of Pathology and Diagnostics, University and Azienda Ospedaliera Universitaria Integrata, Verona, Italy 5 Biostatistics, Regina Elena National Cancer Institute, Rome, Italy 6 Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy * These authors have contributed equally to this work Correspondence to: Aldo Scarpa, email: // Keywords : lung cancer, EGFR, next-generation sequencing, gefitinib Received : February 05, 2015 Accepted : March 01, 2015 Published : March 30, 2015 Abstract Cancer molecular heterogeneity might explain the variable response of EGFR mutant lung adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the mutational status of 22 cancer genes by next-generation sequencing (NGS) in poor, intermediate or good responders to first-line gefitinib. Clinical outcome was correlated with Additional Coexisting Mutations (ACMs) and the EGFR Proportion of Mutated Alleles (PMA). Thirteen ACMs were found in 10/17 patients: TP53 (n=6), KRAS (n=2), CTNNB1 (n=2), PIK3CA , SMAD4 and MET (n=1 each). TP53 mutations were exclusive of poor/intermediate responders (66.7% versus 0, p=0.009). Presence of ACMs significantly affected both PFS (median 3.0 versus 12.3 months, p=0.03) and survival (3.6 months versus not reached, p=0.03). TP53 mutation was the strongest negative modifier (median PFS 4.0 versus 14.0 months). Higher EGFR PMA was present in good versus poor/intermediate responders. Median PFS and survival were longer in patients with EGFR PMA ≥0.36 (12.0 versus 4.0 months, p=0.31; not reached versus 18.0 months, p=0.59). Patients with an EGFR PMA ≥0.36 and no ACMs fared significantly better (p=0.03), with a trend towards increased survival (p=0.06). Our exploratory data suggest that a quantitative (PMA) and qualitative (ACMs) molecular heterogeneity assessment using NGS might be useful for a better selection of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3727

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 73

Metadata

Authors
Bria, E., Pilotto, S., Amato, E., Fassan, M., Novello, S., Peretti, U., Vavalà, T., Kinspergher, S., Righi, L., Santo, A., Brunelli, M., Corbo, V., Giglioli, E., Sperduti, I., Milella, M., Chilosi, M., Scarpa, A., & Tortora, G.
Venue
Oncotarget
Published
2015-03-30
Volume
6
Issue
14
Pages
12783-12795
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2170899818
Cited by
73
References
15
FWCI
6.90
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. https://app.cochat.ai/papers/10.18632/oncotarget.3727
The paper
Bria, E., Pilotto, S., Amato, E., Fassan, M., Novello, S., Peretti, U., Vavalà, T., Kinspergher, S., Righi, L., Santo, A., Brunelli, M., Corbo, V., Giglioli, E., Sperduti, I., Milella, M., Chilosi, M., Scarpa, A., & Tortora, G. (2015). Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget. https://doi.org/10.18632/oncotarget.3727

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.